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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
The main objective is to assess the results at two years of ab interno trabecular bypass surgery with Hydrus for OAG in comparison
to conventional medical, laser, or surgical treatment in terms of efficacy and safety. A secondary objective will be to examine the
effects of Hydrus surgery in people who have concomitant phacoemulsification in comparison to those who do not have concomitant
phacoemulsification.
B A C K G R O U N D
Description of the condition
Glaucoma is a chronic progressive optic neuropathy, affecting up
to 4% of people by the age of 80 years (Burr 2007). It is the
leading cause of irreversible blindness, affecting 60 million peo-
ple globally (Quigley 2006). This figure is expected to increase to
80 million people by 2020. Open angle glaucoma (OAG) is the
commonest type, accounting for three-quarters of cases (Quigley
2006). In one large population cohort, one in six patients with
OAGbecame bilaterally blind (Peters 2013). The only provenway
to prevent vision loss is to reduce the pressure inside the eye (in-
traocular pressure) over the long term (AGIS 2000; CNTG Study
Group 1998; Heijl 2002; Kass 2002). Approaches to reducing in-
traocular pressure (IOP) includemedical therapy, laser treatments,
and surgery. Because commercially available eye-drop preparations
have a short-lasting effect, medical therapy requires eye-drops to
be instilled one ormore times daily for life. Adherence is very poor,
even if use is monitored (Friedman 2009; Okeke 2009). Conven-
tional surgical techniques such as trabeculectomy are associated
with significant risks, with more than 40% of patients develop-
ing perioperative complications (Kirwan 2013; Lichter 2001) and
reoperation being needed in 7% to 18% (Gedde 2012; Kirwan
2013). Therefore, they are often reserved for disease that is pro-
gressing despite other treatments (King 2013).
Description of the intervention
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Recently, a number of minimally-invasive surgical techniques have
been developed, with the aim of achieving long-term reduction
of IOP with a better safety profile than conventional surgery (
Francis 2011). Among them, ab interno trabecular bypass surgery
with Hydrus Schlemm´ s canal Microstent (Ivantis Inc., Irvine,
California) is a CE marked treatment.
How the intervention might work
The trabecular meshwork is the main site of resistance to outflow
from the eye of aqueous humour (Overby 2009). The HydrusMi-
crostent is an 8mm long crescent-shaped open structure, curved to
match the shape of Schlemm’s canal. This is intended to promote
outflow of aqueous humour, and thereby reduce IOP. The micros-
tent is implanted ab interno through a clear corneal incision into
Schlemm’s canal using a preloaded hand-held injector. After being
implanted, the microstent bypasses the trabecular meshwork and
dilates Schlemm’s canal over three clock hours to provide direct
aqueous access from the anterior chamber to multiple collector
channels (Pfeiffer 2015).
Why it is important to do this review
Consultationwith patients and healthcare professionals has identi-
fied a need for better treatments for glaucoma (James Lind Alliance
2013). Minimally-invasive glaucoma procedures carry the possi-
bility of safe and effective long-term reduction of IOP, remov-
ing concerns about permanent vision loss due to nonadherence
to eye-drops. A single treatment may also be more acceptable to
patients than daily and indefinite self-administration of eye-drops.
To date, approximately 2,700 treatments have been performed
worldwide in either feasibility studies, randomised controlled tri-
als, or data registries (Ivantis Inc., on file). In the light of the po-
tential benefits for patients and the widespread uptake of the tech-
nique, it is important to critically evaluate the evidence for the
efficacy and safety of treatment with Hydrus. Importantly, Hy-
drus implantation surgery may be combined with phacoemulsifi-
cation (cataract surgery), a sight-restoring operation to remove the
natural lens of the eye when it has lost clarity. Since phacoemul-
sification itself reduces IOP (Mansberger 2012), we will specif-
ically examine the evidence for efficacy of Hydrus treatment in
people who have concomitant phacoemulsification in compari-
son to those who do not have concomitant phacoemulsification.
This Cochrane review will be conducted in parallel with other
reviews currently undertaken by the Cochrane Eyes and Vision
MIGS Consortium, which includes minimally-invasive glaucoma
surgery (MIGS) techniques and devices such as the Trabectome
(NeoMedix, Tustin, California) (Hu 2016), endoscopic cytopho-
tocoagulation (ECP) (Endo Optiks, Waltham, Massachusetts),
XEN Glaucoma Implant (AqueSys Implant, Aliso Viejo, Califor-
nia) and IStent or IStent inject (Glaukos Corporation, Laguna
Hills, California).
O B J E C T I V E S
Themain objective is to assess the results at two years of ab interno
trabecular bypass surgery with Hydrus for OAG in comparison
to conventional medical, laser, or surgical treatment in terms of
efficacy and safety. A secondary objective will be to examine the
effects of Hydrus surgery in people who have concomitant pha-
coemulsification in comparison to those who do not have con-
comitant phacoemulsification.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include randomised controlled trials (RCTs) only. We will
include reports of RCTs prepared in any language irrespective of
their publication status.
Types of participants
Participants will have OAG of any type, including primary and
secondary OAG.Closed angle glaucoma will be excluded. As there
are no universally-accepted criteria by which glaucoma may be de-
fined, we will permit studies to use their own definitions of glau-
coma (provided these are clearly stated). In addition, participants
with ocular hypertension, normal tension glaucoma, or possible
glaucoma (suspects for glaucoma) will be included. We will not
apply any restrictions regarding location, setting, or demographic
factors.
Types of interventions
The intervention will be ab interno trabecular bypass surgery with
Hydrus (Ivantis Inc., Irvine, California).
Wewill compare ab interno trabecular bypass surgery withHydrus
to:
1. laser treatment (selective laser trabeculoplasty or argon laser
trabeculoplasty);
2. other MIGS techniques;
3. conventional glaucoma surgery (trabeculectomy)
4. medical therapy; or
5. in combination with phacoemulsification compared with
phacoemulsification alone (since phacoemulsification cataract
surgery is known to reduce IOP (Mansberger 2012)).
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Types of outcome measures
We will not use the reporting of particular outcomes as a criterion
for eligibility for review. We will not exclude studies from review
solely on the grounds of an outcome of interest not being reported.
Primary outcomes
The primary outcome will be the proportion of participants who
are drop-free (not using eye-drops) at two years after randomisa-
tion.
Several different glaucoma outcome measures have been specified
as primary outcomes in other Cochrane Reviews and protocols
(Ismail 2015). A recent study classified IOP, visual field, safety,
and anatomic outcomes as being highly important to glaucoma
experts (Ismail 2016). A panel of patients from the Patient and
Public Involvement Group of the National Institute for Health
Research (NIHR) Biomedical Research Centre for Ophthalmol-
ogy identified drop-free disease control as a highly valued outcome
(unpublished). We chose a participant-centred primary outcome.
Secondary outcomes
Secondary outcomes will be:
1. Mean change in IOP, measured using Goldmann
applanation tonometry, from randomisation to two years.
2. The proportions of participants experiencing intra- and
postoperative complications from randomisation to two-year
follow-up, including but not restricted to the following:
◦ Loss of visual acuity (more than two Snellen lines or
more than 0.3 logMAR, according to the method of recording
visual acuity; or loss of light perception).
◦ Bleeding, as recorded by the investigators.
◦ Endophthalmitis, as recorded by the investigators.
◦ IOP spikes (postoperative rise in IOP, measured using
Goldmann applanation tonometry, of more than 10 mmHg
compared to the previous assessment, including during the first
postoperative month).
◦ Secondary surgery, as recorded by the investigators.
3. Change in health-related quality of life measure, from
randomisation to two-year follow-up.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist will search
the following electronic databases for randomised controlled trials
and controlled clinical trials. There will be no language or publi-
cation year restrictions.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (which contains the Cochrane Eyes and Vision
Trials Register) in the Cochrane Library (latest issue) (Appendix
1);
• MEDLINE Ovid (1946 to present) (Appendix 2);
• Embase Ovid (1980 to present) (Appendix 3);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch
(Appendix 4);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov) (Appendix 5);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (www.who.int/ictrp)
(Appendix 6).
Searching other resources
We will search the reference lists of included studies for other
possible studies and will contact any individuals or organisations
who, we believe, may have conducted or be conducting relevant
RCTs. We will also search the website of themanufacturer (Ivantis
Inc., Irvine, California; www.ivantisinc.com) for any information
on forthcoming trials.
Data collection and analysis
Selection of studies
Two review authors working independently will screen titles and
abstracts of all articles identified by the search using web-based on-
line review management software (Covidence 2015). If abstracts
are not available, we will screen full-text articles. Two review au-
thors will independently assess full-text reports of all potentially
eligible studies. If there is disagreement regarding eligibility, a third
review author will arbitrate. If any full-text reports are rejected, we
will record the reasons for this.
Data extraction and management
We will extract data from reports of included studies using a data
collection form, which will be developed and piloted on the first
five studies included. Two review authors will work independently
to extract study characteristics from reports of each study and enter
the data into Review Manager 5 (RevMan 5) (Review Manager 5
2014). If there is disagreement, a third independent review author
will arbitrate.
We will collect the following information on the characteristics of
included studies (Appendix 7):
• Year of publication.
• Year of study.
• Country of study.
• Sample size.
• Participation rate.
• Method of recruitment.
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• Eligibility criteria.
• Diagnostic criteria.
• Method of randomisation.
• Method of masking.
• Number of study arms.
• Types of participants.
• Types of interventions.
• Types of comparators.
• Use of phacoemulsification at the same time as the
intervention.
We will collect the the following data regarding outcomes
(Appendix 7):
• IOP at baseline.
• IOP at follow-up.
• Number of glaucoma medications at baseline.
• Number of glaucoma medications at follow-up.
• Intraoperative complications.
• Postoperative complications or secondary surgery.
• Duration of follow-up.
• Loss to follow-up.
• Intervals at which outcomes were assessed.
Where data on included studies are missing or unclear, we will
contact the individuals or organisations involved to obtain clari-
fication. We will collect and use the most detailed numerical data
available to facilitate analyses of included studies. We will attempt
to obtain these data from individuals or organisations in prefer-
ence to less precise methods such as extracting numeric data from
graphs. If this is necessary, two independent review authors will
extract the data and a third review author will arbitrate, in case of
disagreement.
Assessment of risk of bias in included studies
We will use the latest version of the Cochrane ’Risk of bias’ tool
as described in Chapter 8 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011) to assess the risk of bias
and assign judgements of this for included studies.
Measures of treatment effect
The primary outcome is the proportion of participants who are
drop-free two years after randomisation. We will use a risk ratio
as the treatment effect measure. In assessing this effect measure,
we will report how prescribing of IOP-lowering eye-drops was
determined during follow-up.Wewill examinewhether the people
measuring IOP and those deciding upon the prescribing of IOP-
lowering eye-drops were masked to treatment group.
We will report mean change in IOP from randomisation to two
years after randomisation. Secondary safety outcomes will be re-
ported as risk ratios. Health-related quality of life outcomes will
be reported as differences in means or risk ratios for continuous
and binary data, respectively.
Unit of analysis issues
We will assess whether included studies have included one or two
eyes from each subject and whether or not randomisation has been
conducted at the level of the participant or the eye. There is a
potential for medical treatments, such as topical beta blockers used
for one eye, to influence the outcome in the other eye (Piltz 2000).
Surgery to lower IOP in one eye may also affect the IOP of the
fellow eye (Radcliffe 2010). Therefore, we will exclude studies that
have adopted a paired design.
Dealing with missing data
We will endeavour to minimize missing outcome data by con-
tacting individuals and organisations to obtain them. If the data
are unavailable but the level of missing data in each group and
reasons for missing data in each group are similar we may simply
analyse available-case data if an intention-to-treat (ITT) analysis
has not been performed.We will report if authors have conducted
their own ITT analysis despite missing data, but we will document
whether they provide any justification for the method they have
used to deal with missing data and whether they have compared
their ITT result with an available-case result.
Assessment of heterogeneity
Wewill assess the heterogeneity between trials by careful examina-
tion of the study reports, assessing forest plots and an examination
of the I2 value. We will consider I2 values greater than 50% as
indicative of substantial heterogeneity, suggestive that meta anal-
ysis might not be wise - however, consideration will be given to
the consistency of the effect estimates. If all estimates are in the
same direction, we might meta-analyse even where heterogeneity
is evident; we will comment on the heterogeneity.
Assessment of reporting biases
We will use a funnel plot to assess the risk of publication bias if
there are more than 10 trials within our review.
Data synthesis
We will undertake a meta-analysis where data appear clinically,
methodologically, and statistically homogeneous. We will check
that participants, interventions, comparators, and outcomes are
sufficiently similar to give a clinically meaningful result and that
our I2 result does not indicate considerable inconsistency (i.e. I
2 less than 50%). If all estimates are in the same direction, we
might meta-analyse even where heterogeneity is evident but will
comment on this. We will use a random-effects model unless there
are fewer than three eligible studies, in which case, we will use a
fixed-effect model.
4Ab interno trabecular bypass surgery with Schlemm´ s Canal Microstent (Hydrus) for open angle glaucoma (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Subgroup analysis and investigation of heterogeneity
We will undertake a subgroup analysis. The effect modifier to be
examined will be use of phacoemulsification as a cointervention.
Phacoemulsification has been shown to reduce IOP (Mansberger
2012). We will therefore analyse whether the effect of Hydrus
surgery differs depending on whether phacoemulsification is used
as a cointervention.
Sensitivity analysis
We will assess the impact of including studies at high risk of bias
for an outcome in one or more key domains.
Summary of findings
We will prepare tables to summarise the findings of the review,
including the assessment of the certainty of evidence for all out-
comes using the GRADE approach (GRADEpro 2014).
We will report the following outcomes in the ’Summary of find-
ings’ table and the comparison groups described under Types
of interventions: ab interno trabecular bypass surgery with Hy-
drus (Ivantis Inc., Irvine, California) compared with laser treat-
ment, other MIGS techniques, conventional glaucoma surgery
(trabeculectomy), medical therapy or in combination with pha-
coemulsification compared with phacoemulsification alone.
1. Proportion of participants who are drop-free (not using eye-
drops) at two years follow-up.
2. Mean change in number of IOP-lowering drops taken per
day from baseline to two years follow-up.
3. Mean change in IOP, measured using Goldmann
applanation tonometry, from baseline to two years follow-up.
4. Health-related quality of life at two years follow-up.
5. Intraoperative complications.
6. Postoperative complications, up to two years follow-up.
7. Secondary glaucoma surgery, including laser, as recorded by
the investigators of the included trials between baseline and two
years follow-up.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Glaucoma, Open-Angle] explode all trees
#2 MeSH descriptor: [Intraocular Pressure] explode all trees
#3 MeSH descriptor: [Ocular Hypertension] explode all trees
#4 OAG or POAG or IOP or OHT
#5 simple near/3 glaucoma*
#6 open near/2 angle near/2 glaucoma*
#7 chronic near/2 glaucoma*
#8 secondary near/2 glaucoma*
#9 low near/2 tension near/2 glaucoma*
#10 low near/2 pressure near/2 glaucoma*
#11 normal near/2 tension near/2 glaucoma*
#12 normal near/2 pressure near/2 glaucoma*
#13 pigment near/2 glaucoma*
#14 MeSH descriptor: [Exfoliation Syndrome] this term only
#15 exfoliat* near/2 syndrome*
#16 exfoliat* near/2 glaucoma*
#17 pseudoexfoliat* near/2 syndrome*
#18p seudoexfoliat* near/2 glaucoma*
#19 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
#20 Schlemm* near/4 (microstent* or scaffold*)
#21Hydrus
#22 #20 or #21
#23 #19 and #22
Appendix 2. MEDLINE Ovid search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp glaucoma open angle/
14. exp intraocular pressure/
15. ocular hypertension/
16. (OAG or POAG or IOP or OHT).tw.
17. (simple$ adj3 glaucoma$).tw.
18. (open adj2 angle adj2 glaucoma$).tw.
19. (primary adj2 glaucoma$).tw.
20. (chronic adj2 glaucoma$).tw.
21. (secondary adj2 glaucoma$).tw.
22. (low adj2 tension adj2 glaucoma$).tw.
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23. (low adj2 pressure adj2 glaucoma$).tw.
24. (normal adj2 tension adj2 glaucoma$).tw.
25. (normal adj2 pressure adj2 glaucoma$).tw.
26. (pigment$ adj2 glaucoma$).tw.
27. exfoliation syndrome/
28. (exfoliat$ adj2 syndrome$).tw.
29. (exfoliat$ adj2 glaucoma$).tw.
30. (pseudoexfoliat$ adj2 syndrome$).tw.
31. (pseudoexfoliat$ adj2 glaucoma$).tw.
32. or/13-31
33. (Schlemm$ adj4 (microstent$ or scaffold$)).tw.
34. Hydrus.tw.
35. or/33-34
36. 32 and 35
37. 12 and 36
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase Ovid search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. open angle glaucoma/
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34. intraocular pressure/
35. intraocular hypertension/
36. (OAG or POAG or IOP or OHT).tw.
37. (open adj2 angle adj2 glaucoma$).tw.
38. (primary adj2 glaucoma$).tw.
39. (chronic adj2 glaucoma$).tw.
40. (secondary adj2 glaucoma$).tw.
41. (low adj2 tension adj2 glaucoma$).tw.
42. (low adj2 pressure adj2 glaucoma$).tw.
43. (normal adj2 tension adj2 glaucoma$).tw.
44. (normal adj2 pressure adj2 glaucoma$).tw.
45. (pigment$ adj2 glaucoma$).tw.
46. exfoliation syndrome/
47. (exfoliat$ adj2 syndrome$).tw.
48. (exfoliat$ adj2 glaucoma$).tw.
49. (pseudoexfoliat$ adj2 syndrome$).tw.
50. (pseudoexfoliat$ adj2 glaucoma$).tw.
51. or/33-50
52. (Schlemm$ adj4 (microstent$ or scaffold$)).tw.
53. Hydrus.tw.
54. 52 or 53
55. 51 and 54
56. 32 and 55
Appendix 4. ISRCTN search strategy
(Schlemms canal microstent OR Schlemms canal scaffold OR HYDRUS)
Appendix 5. ClinicalTrials.gov search strategy
(Schlemms canal microstent OR Schlemms canal scaffold OR HYDRUS)
Appendix 6. WHO ICTRP search strategy
Schlemms canal microstent OR Schlemms canal scaffold OR HYDRUS
Appendix 7. Data on study characteristics
Mandatory items Optional items
Methods
Study design ·Parallel group RCT i.e. people randomised
to treatment
· Within-person RCT i.e. eyes randomised
to treatment
· Cluster RCT i.e. communities randomised
Number of study arms
Method of randomisation
Exclusions after randomisation
Losses to follow-up
Number randomised/analysed
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(Continued)
to treatment
· Cross-over RCT
· Other, specify
Method of masking
How were missing data handled? e.g. avail-
able case analysis, imputation methods
Reported power calculation (Y/N), if yes,
sample size and power
Unusual study design/issues
Eyes
Unit of randomisation/ unit of analysis
· One eye included in study, specify how
eye selected
· Two eyes included in study, both eyes
received same treatment, briefly specify
how analysed (best/worst/average/both and
adjusted for within person correlation/both
and not adjusted for within person correla-
tion) and specify if mixture of one eye and two
eyes
· Two eyes included in study, eyes re-
ceived different treatments, specify if cor-
rect pair-matched analysis done
Participants
Country - Setting
Ethnic group
Method of recruitment
Participation rate
Equivalence of baseline characteristics (Y/
N)
Diagnostic criteria
Total number of participants This information should be collected for total
study population recruited into the study. If
these data are reported for the people whowere
followed up only, please indicate.
Number (%) of men and women Number (%) of men and women
Average age and age range Average age and age range
Inclusion criteria -
Exclusion criteria -
Interventions
Intervention (n = )
Comparator (n = )
· Number of people randomised to this
group
· Intervention name
· Comparator name
· Specify whether phacoemulsification, or
other intervention, performed at same time
as intervention
Comparator parameters, e.g. dosage of drugs
Outcomes
Primary and secondary outcomes as defined
in study reports
· IOP at baseline
· IOP at follow-up
·Number of glaucomamedications at base-
Planned/actual length of follow-up
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(Continued)
line
· Number of glaucoma medications at fol-
low-up
· Intraoperative complications
· Postoperative complications or secondary
surgery
· Duration of follow-up
· Loss to follow-up
· Intervals at which outcomes assessed
Adverse events reported (Y/N)
Notes
Date conducted Specify dates of recruitment of participants
mm/yr to mm/yr
Full study name: (if applicable)
Date of publication
Reported subgroup analyses (Y/N)
Were trial investigators contacted?Sources of funding -
Declaration of interest -
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• Richard Wormald, Co-ordinating Editor for Cochrane Eyes and Vision (CEV) acknowledges financial support for his CEV
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